Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/30/2025

Citrate Lock for Central Venous Catheters

Mechanism of Action

  • Citrate functions as both an anticoagulant and antimicrobial agent, disrupting the normal coagulation pathway and interfering with bacterial biofilm formation, unlike heparin, which may enhance biofilm growth, citrate actively prevents biofilm formation and has inherent antimicrobial properties 2
  • Citrate's dual action helps maintain catheter patency while reducing infection risk, addressing the two major complications of central venous catheters 3, 4

Formulations and Concentrations

  • The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend using low-concentration citrate (<5%) for CVC locks 5

Efficacy

Infection Prevention

  • A prospective multicenter study showed gentamicin-citrate solution reduced CRBSI by 73% compared to heparin (0.45 vs 1.68 per 1,000 catheter-days) 3

Clinical Applications

  • KDOQI guidelines suggest using low-concentration citrate (<5%) CVC locking solution to help prevent CRBSI and CVC dysfunction 5
  • For hemodialysis catheters with recurrent dysfunction, KDOQI recommends using alteplase or urokinase plus citrate 4% per limb for restoring intraluminal blood flow 5
  • Citrate locks are especially valuable for patients with a history of multiple CRBSIs or those with long-term catheter placement 2

Safety Considerations

  • Currently, there are no FDA-approved commercial lock formulations; solutions are typically prepared locally in hospital pharmacies 2

Practical Implementation

  • The choice between citrate or heparin as a CVC locking solution should be based on patient-specific factors such as bleeding risk and infection history 4
  • Regular monitoring of catheter function and inspection for signs of infection should be performed regardless of the locking solution used 4